Knockdown of caveolin-1 by siRNA inhibits the transformation of mouse hepatoma H22 cells in vitro and in vivo

Oligonucleotides

Volumn 19, Issue 1, 2009, Pages 81-88

  Wang, Shujing ^a   Jia, Li ^a   Zhou, Huimin ^a   Shi, Wei ^a   Zhang, Jianing ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAV 1 SMALL INTERFERING RNA; CAVEOLIN 1; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; GENE SILENCING; HEPATOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CAVEOLIN 1; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; IMMUNOHISTOCHEMISTRY; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 61349096633     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2008.0166     Document Type: Article

References (33)

1. ANDERSON, R.G., and JACOBSON, K. (2002). A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science. 296, 1821-1825.
2. BENDER, F.C., REYMOND, M.A., BRON, C., and QUEST, A.F. (2000). Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60, 5870-5878.
3. COX, A.D. and DER, C.J. (1994). Biological assays for cellular transformation. Methods Enzymol. 238, 277-294.
4. DRAB, M., VERKADE, P., ELGER, M., KASPER, M., LOHN, M., LAUTERBACH, B., MENNE, J., LINDSCHAU, C., MENDE, F., LUFT, F.C., SCHEDL, A., HALLER, H., and KURZCHALIA, T.V. (2001). Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 293, 2449-2452.
5. ENGELMAN, J.A., LEE, R.J., KARNEZIS, A., BEARSS, D.J., WEBSTER, M., SIEGEL, P., MULLER, W.J., WINDLE, J.J., PESTELL, R.G., and LISANTI, M.P. (1998). Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J. Biol. Chem. 273, 20448-20455.
6. FEDOROV, Y., ANDERSON, E.M., BIRMINGHAM, A., REYNOLDS, A., KARPILOW, J., ROBINSON, K., LEAKE, D., MARSHALL, W.S., and KHVOROVA, A. (2006). Off-target effects by siRNA can induce toxic phenotype. RNA. 12, 1188-1196.
7. FIELDING, C.J., and FIELDING, P.E. (2001). Cellular cholesterol efflux. Biochim. Biophys. Acta. 1533, 175-189.
8. FIELDING, P.E., RUSSEL, J.S., SPENCER, T.A., HAKAMATA, H., NAGAO, K., and FIELDING, C.J. (2002). Sterol efflux to apolipoprotein A-I originates from caveolin-rich microdomains and potentiates PDGF-dependent protein kinase activity. Biochemistry. 41, 4929-4937.
9. FIUCCI, G., RAVID, D., REICH, R., and LISCOVITCH, M. (2002). Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene. 21, 2365-2375.
10. GALBIATI, F., RAZANI, B., and LISANTI, M.P. (2001). Emerging themes in lipid rafts and caveolae. Cell. 106, 403-411.
11. GALBIATI, F., VOLONTE, D., ENGELMAN, J.A., WATANABE, G., BURK, R., PESTELL, R.G., and LISANTI, M.P. (1998). Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17, 6633-6648.
12. HEIGHWAY, J., KNAPP, T., BOYCE, L., BRENNAND, S., FIELD, J.K., BETTICHER, D.C., RATSCHILLER, D., GUGGER, M., DONOVAN, M., LASEK, A., and RICKERT, P. (2002). Expression profiling of primary non-small cell lung cancer for target identification. Oncogene. 21, 7749-7763.
13. JIA, L., WANG, S., ZHOU, H., CAO, J., HU, Y., and ZHANG, J. (2006). Caveolin-1 up-regulates CD147 glycosylation and the invasive capability of murine hepatocarcinoma cell lines. Int. J. Biochem. Cell Biol. 38, 1584-1593.
14. KATO, K., HIDA, Y., MIYAMOTO, M., HASHIDA, H., SHINOHARA, T., ITOH, T., OKUSHIBA, S., KONDO, S., and KATOH, H. (2002). Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer. 94, 929-933.
15. KIM, D.H., and ROSSI, J.J. (2007). Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173-184.
16. KOLESKE, A.J., BALTIMORE, D., and LISANTI, M.P. (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proc. Natl. Acad. Sci. U. S. A. 92, 1381-1385.
17. LEE, S.W., REIMER, C.L., OH, P., CAMPBELL, D.B., and SCHNITZER, J.E. (1998). Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 16, 1391-1397.
18. LI, L., REN, C.H., TAHIR, S.A., REN, C., and THOMPSON, T.C. (2003). Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol. Cell. Biol. 23, 9389-9404.
19. LI, L., YANG, G., EBARA, S., SATOH, T., NASU, Y., TIMME, T.L., REN, C., WANG, J., TAHIR, S.A., and THOMPSON, T.C. (2001). Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 61, 4386-4392.
20. LIU, J., LEE, P., GALBIATI, F., KITSIS, R.N., and LISANTI, M.P. (2001). Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am. J. Physiol Cell Physiol. 280, C823-C835.
21. LIU, P., RUDICK, M., and ANDERSON, R.G. (2002). Multiple functions of caveolin-1. J. Biol. Chem. 277, 41295-41298.
22. NASU, Y., TIMME, T.L., YANG, G., BANGMA, C.H., LI, L., REN, C., PARK, S.H., DELEON, M., WANG, J., and THOMPSON, T.C. (1998). Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat. Med. 4, 1062-1064.
23. OKAMOTO, T., SCHLEGEL, A., SCHERER, P.E., and LISANTI, M.P. (1998). Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J. Biol. Chem. 273, 5419-5422.
24. PERSENGIEV, S.P., ZHU, X., and GREEN, M.R. (2004). Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA. 10, 12-18.
25. PFLUG, B.R., REITER, R.E., and NELSON, J.B. (1999). Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate. 40, 269-273.
26. RAJJAYABUN, P.H., GARG, S., DURKAN, G.C., CHARLTON, R., ROBINSON, M.C., and MELLON, J.K. (2001). Caveolin-1 expression is associated with high-grade bladder cancer. Urology. 58, 811-814.
27. RANA, T.M. (2007). Illuminating the silence: understanding the structure and function of small RNAs. Nat. Rev. Mol. Cell Biol. 8, 23-36.
28. RAZANI, B., SCHLEGEL, A., LIU, J., and LISANTI, M.P. (2001). Caveolin-1, a putative tumour suppressor gene. Biochem. Soc. Trans. 29, 494-499.
29. ROSSI, J.J. (2008). Realizing the promise of RNAi. Mol. Ther. 16, 810-811.
30. SELL, S., and LEFFERT, H.L. (2008). Liver cancer stem cells. J. Clin. Oncol. 26, 2800-2805.
31. WIECHEN, K., DIATCHENKO, L., AGOULNIK, A., SCHARFF, K.M., SCHOBER, H., ARLT, K., ZHUMABAYEVA, B., SIEBERT, P.D., DIETEL, M., SCHAFER, R., and SERS, C. (2001). Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am. J. Pathol. 159, 1635-1643.
32. WILLIAMS, T.M., MEDINA, F., BADANO, I., HAZAN, R.B., HUTCHINSON, J., MULLER, W.J., CHOPRA, N.G., SCHERER, P.E., PESTELL, R.G., and LISANTI, M.P. (2004). Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J. Biol. Chem. 279, 51630-51646.
33. ZHANG, D., SALTO-TELLEZ, M., PUTTI, T.C., DO, E., and KOAY, E.S. (2003). Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod. Pathol. 16, 79-84.